Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated:  8/28/2015
The Polyclinic
mi
from
Seattle, WA
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated: 8/28/2015
The Polyclinic
mi
from
Seattle, WA
Click here to add this to my saved trials
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated:  8/28/2015
University of Washington Medical Center
mi
from
Seattle, WA
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated: 8/28/2015
University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated:  8/28/2015
Cancer Care Northwest - Spokane South
mi
from
Spokane, WA
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated: 8/28/2015
Cancer Care Northwest - Spokane South
mi
from
Spokane, WA
Click here to add this to my saved trials
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated:  8/28/2015
Wenatchee Valley Hospital and Clinics
mi
from
Wenatchee, WA
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated: 8/28/2015
Wenatchee Valley Hospital and Clinics
mi
from
Wenatchee, WA
Click here to add this to my saved trials
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated:  8/28/2015
West Virginia University Charleston
mi
from
Charleston, WV
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated: 8/28/2015
West Virginia University Charleston
mi
from
Charleston, WV
Click here to add this to my saved trials
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated:  8/28/2015
Marshfield Clinic - Chippewa Center
mi
from
Chippewa Falls, WI
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated: 8/28/2015
Marshfield Clinic - Chippewa Center
mi
from
Chippewa Falls, WI
Click here to add this to my saved trials
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated:  8/28/2015
Marshfield Clinic Cancer Center at Sacred Heart
mi
from
Eau Claire, WI
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated: 8/28/2015
Marshfield Clinic Cancer Center at Sacred Heart
mi
from
Eau Claire, WI
Click here to add this to my saved trials
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated:  8/28/2015
Sacred Heart Hospital
mi
from
Eau Claire, WI
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated: 8/28/2015
Sacred Heart Hospital
mi
from
Eau Claire, WI
Click here to add this to my saved trials
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated:  8/28/2015
Marshfield Clinic
mi
from
Marshfield, WI
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated: 8/28/2015
Marshfield Clinic
mi
from
Marshfield, WI
Click here to add this to my saved trials
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated:  8/28/2015
Saint Joseph's Hospital
mi
from
Marshfield, WI
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated: 8/28/2015
Saint Joseph's Hospital
mi
from
Marshfield, WI
Click here to add this to my saved trials
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated:  8/28/2015
Marshfield Clinic Minocqua Center
mi
from
Minocqua, WI
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated: 8/28/2015
Marshfield Clinic Minocqua Center
mi
from
Minocqua, WI
Click here to add this to my saved trials
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated:  8/28/2015
Marshfield Clinic at James Beck Cancer Center
mi
from
Rhinelander, WI
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated: 8/28/2015
Marshfield Clinic at James Beck Cancer Center
mi
from
Rhinelander, WI
Click here to add this to my saved trials
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated:  8/28/2015
Marshfield Clinic Rice Lake Center
mi
from
Rice Lake, WI
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated: 8/28/2015
Marshfield Clinic Rice Lake Center
mi
from
Rice Lake, WI
Click here to add this to my saved trials
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated:  8/28/2015
Saint Michael's Hospital
mi
from
Stevens Point, WI
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated: 8/28/2015
Saint Michael's Hospital
mi
from
Stevens Point, WI
Click here to add this to my saved trials
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated:  8/28/2015
Marshfield Clinic - Wausau Center
mi
from
Wausau, WI
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated: 8/28/2015
Marshfield Clinic - Wausau Center
mi
from
Wausau, WI
Click here to add this to my saved trials
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated:  8/28/2015
Diagnostic and Treatment Center
mi
from
Weston, WI
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated: 8/28/2015
Diagnostic and Treatment Center
mi
from
Weston, WI
Click here to add this to my saved trials
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated:  8/28/2015
Marshfield Clinic - Weston Center
mi
from
Weston, WI
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated: 8/28/2015
Marshfield Clinic - Weston Center
mi
from
Weston, WI
Click here to add this to my saved trials
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated:  8/28/2015
Marshfield Clinic - Wisconsin Rapids Center
mi
from
Wisconsin Rapids, WI
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated: 8/28/2015
Marshfield Clinic - Wisconsin Rapids Center
mi
from
Wisconsin Rapids, WI
Click here to add this to my saved trials
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated:  8/28/2015
Welch Cancer Center
mi
from
Sheridan, WY
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated: 8/28/2015
Welch Cancer Center
mi
from
Sheridan, WY
Click here to add this to my saved trials
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated:  8/28/2015
Tom Baker Cancer Centre
mi
from
Calgary,
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated: 8/28/2015
Tom Baker Cancer Centre
mi
from
Calgary,
Click here to add this to my saved trials
Dose-Escalation Study of Intensity-Modulated Radiotherapy(IMRT)in Patients With Unresectable Pancreatic Cancer
A Phase I/II Radiation Dose-Escalation Study of Intensity-Modulated Radiotherapy (IMRT) With Concurrent Gemcitabine in Patients With Unresectable Pancreatic Cancer
Status: Enrolling
Updated:  8/28/2015
Rush University Medical Center
mi
from
Chicago, IL
Dose-Escalation Study of Intensity-Modulated Radiotherapy(IMRT)in Patients With Unresectable Pancreatic Cancer
A Phase I/II Radiation Dose-Escalation Study of Intensity-Modulated Radiotherapy (IMRT) With Concurrent Gemcitabine in Patients With Unresectable Pancreatic Cancer
Status: Enrolling
Updated: 8/28/2015
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Dose-Escalation Study of Intensity-Modulated Radiotherapy(IMRT)in Patients With Unresectable Pancreatic Cancer
A Phase I/II Radiation Dose-Escalation Study of Intensity-Modulated Radiotherapy (IMRT) With Concurrent Gemcitabine in Patients With Unresectable Pancreatic Cancer
Status: Enrolling
Updated:  8/28/2015
University of Michigan
mi
from
Ann Arbor, MI
Dose-Escalation Study of Intensity-Modulated Radiotherapy(IMRT)in Patients With Unresectable Pancreatic Cancer
A Phase I/II Radiation Dose-Escalation Study of Intensity-Modulated Radiotherapy (IMRT) With Concurrent Gemcitabine in Patients With Unresectable Pancreatic Cancer
Status: Enrolling
Updated: 8/28/2015
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated:  8/28/2015
City of Hope Cancer Center
mi
from
Duarte, CA
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated: 8/28/2015
City of Hope Cancer Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated:  8/28/2015
Kenneth J. Norris Jr. Comprehensive Cancer Center, Keck School of Medicine, University of Southern California
mi
from
Los Angeles, CA
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated: 8/28/2015
Kenneth J. Norris Jr. Comprehensive Cancer Center, Keck School of Medicine, University of Southern California
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated:  8/28/2015
Stanford University
mi
from
Stanford, CA
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated: 8/28/2015
Stanford University
mi
from
Stanford, CA
Click here to add this to my saved trials
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated:  8/28/2015
Robert H. Lurie Comprehensive Cancer Center, Center of Northwestern University
mi
from
Chicago, IL
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated: 8/28/2015
Robert H. Lurie Comprehensive Cancer Center, Center of Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated:  8/28/2015
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated: 8/28/2015
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated:  8/28/2015
Boston Med Ctr
mi
from
Boston, MA
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated: 8/28/2015
Boston Med Ctr
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated:  8/28/2015
Lahey Clinic
mi
from
Burlington, MA
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated: 8/28/2015
Lahey Clinic
mi
from
Burlington, MA
Click here to add this to my saved trials
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated:  8/28/2015
University of Michigan
mi
from
Ann Arbor, MI
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated: 8/28/2015
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated:  8/28/2015
Wayne State University/Karmanos Cancer Institute
mi
from
Detroit, MI
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated: 8/28/2015
Wayne State University/Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated:  8/28/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated: 8/28/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated:  8/28/2015
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated: 8/28/2015
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated:  8/28/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated: 8/28/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated:  8/28/2015
University of Utah, Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated: 8/28/2015
University of Utah, Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated:  8/28/2015
Univ of Washington
mi
from
Seattle, WA
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated: 8/28/2015
Univ of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
A Pilot Trial of Itraconazole Pharmacokinetics in Patients With Metastatic Breast Cancer
A Pilot Trial of Itraconazole Pharmacokinetics in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  8/28/2015
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
A Pilot Trial of Itraconazole Pharmacokinetics in Patients With Metastatic Breast Cancer
A Pilot Trial of Itraconazole Pharmacokinetics in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 8/28/2015
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer
A Phase Ib Open-label Clinical Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 Plus Cetuximab (Erbitux®) in Patients With Non-small Cell Lung Cancer With Progression Following Prior Erlotinib (Tarceva®) or Gefitinib (Iressa®)
Status: Enrolling
Updated:  8/29/2015
1199.14.1190 Boehringer Ingelheim Investigational Site
mi
from
Aurora, CO
Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer
A Phase Ib Open-label Clinical Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 Plus Cetuximab (Erbitux®) in Patients With Non-small Cell Lung Cancer With Progression Following Prior Erlotinib (Tarceva®) or Gefitinib (Iressa®)
Status: Enrolling
Updated: 8/29/2015
1199.14.1190 Boehringer Ingelheim Investigational Site
mi
from
Aurora, CO
Click here to add this to my saved trials
Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer
A Phase Ib Open-label Clinical Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 Plus Cetuximab (Erbitux®) in Patients With Non-small Cell Lung Cancer With Progression Following Prior Erlotinib (Tarceva®) or Gefitinib (Iressa®)
Status: Enrolling
Updated:  8/29/2015
1199.15.10028 Boehringer Ingelheim Investigational Site
mi
from
New Haven, CT
Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer
A Phase Ib Open-label Clinical Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 Plus Cetuximab (Erbitux®) in Patients With Non-small Cell Lung Cancer With Progression Following Prior Erlotinib (Tarceva®) or Gefitinib (Iressa®)
Status: Enrolling
Updated: 8/29/2015
1199.15.10028 Boehringer Ingelheim Investigational Site
mi
from
New Haven, CT
Click here to add this to my saved trials
Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer
A Phase Ib Open-label Clinical Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 Plus Cetuximab (Erbitux®) in Patients With Non-small Cell Lung Cancer With Progression Following Prior Erlotinib (Tarceva®) or Gefitinib (Iressa®)
Status: Enrolling
Updated:  8/29/2015
Boehringer Ingelheim Investigational Site
mi
from
New York, NY
Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer
A Phase Ib Open-label Clinical Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 Plus Cetuximab (Erbitux®) in Patients With Non-small Cell Lung Cancer With Progression Following Prior Erlotinib (Tarceva®) or Gefitinib (Iressa®)
Status: Enrolling
Updated: 8/29/2015
Boehringer Ingelheim Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer
A Phase Ib Open-label Clinical Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 Plus Cetuximab (Erbitux®) in Patients With Non-small Cell Lung Cancer With Progression Following Prior Erlotinib (Tarceva®) or Gefitinib (Iressa®)
Status: Enrolling
Updated:  8/29/2015
1200.71.1002 Boehringer Ingelheim Investigational Site
mi
from
Nashville, TN
Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer
A Phase Ib Open-label Clinical Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 Plus Cetuximab (Erbitux®) in Patients With Non-small Cell Lung Cancer With Progression Following Prior Erlotinib (Tarceva®) or Gefitinib (Iressa®)
Status: Enrolling
Updated: 8/29/2015
1200.71.1002 Boehringer Ingelheim Investigational Site
mi
from
Nashville, TN
Click here to add this to my saved trials
Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer
A Phase Ib Open-label Clinical Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 Plus Cetuximab (Erbitux®) in Patients With Non-small Cell Lung Cancer With Progression Following Prior Erlotinib (Tarceva®) or Gefitinib (Iressa®)
Status: Enrolling
Updated:  8/29/2015
1200.71.2002 Boehringer Ingelheim Investigational Site
mi
from
Amsterdam,
Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer
A Phase Ib Open-label Clinical Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 Plus Cetuximab (Erbitux®) in Patients With Non-small Cell Lung Cancer With Progression Following Prior Erlotinib (Tarceva®) or Gefitinib (Iressa®)
Status: Enrolling
Updated: 8/29/2015
1200.71.2002 Boehringer Ingelheim Investigational Site
mi
from
Amsterdam,
Click here to add this to my saved trials
A Study of the Interaction of Rifampin and Vinflunine in Subjects With Advanced Cancer
Effect of Rifampin on the Pharmacokinetics of Intravenous (IV) Vinflunine in Subjects With Advanced Cancer
Status: Enrolling
Updated:  8/31/2015
Local Institution
mi
from
Detroit, MI
A Study of the Interaction of Rifampin and Vinflunine in Subjects With Advanced Cancer
Effect of Rifampin on the Pharmacokinetics of Intravenous (IV) Vinflunine in Subjects With Advanced Cancer
Status: Enrolling
Updated: 8/31/2015
Local Institution
mi
from
Detroit, MI
Click here to add this to my saved trials
A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma
A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma
Status: Enrolling
Updated:  8/31/2015
University of Michigan
mi
from
Ann Arbor, MI
A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma
A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma
Status: Enrolling
Updated: 8/31/2015
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  8/31/2015
University of California, San Diego Medical Center
mi
from
La Jolla, CA
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 8/31/2015
University of California, San Diego Medical Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  8/31/2015
Palm Beach Institute of Hematology and Oncology
mi
from
Boynton Beach, FL
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 8/31/2015
Palm Beach Institute of Hematology and Oncology
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  8/31/2015
University of Miami
mi
from
Miami, FL
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 8/31/2015
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  8/31/2015
Medical Oncology LLC
mi
from
Baton Rouge, LA
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 8/31/2015
Medical Oncology LLC
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  8/31/2015
Annapolis Oncology Center
mi
from
Annapolis, MD
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 8/31/2015
Annapolis Oncology Center
mi
from
Annapolis, MD
Click here to add this to my saved trials
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  8/31/2015
Dana-Farber Cancer Center
mi
from
Boston, MA
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 8/31/2015
Dana-Farber Cancer Center
mi
from
Boston, MA
Click here to add this to my saved trials